Form 4: AngioDynamics CEO Disposes of Shares for Tax Obligations
Insider Transaction Report
AngioDynamics President and CEO, James C. Clemmer, disposed of common stock to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- James C. Clemmer, President and CEO, and Director of AngioDynamics Inc. (ANGO), reported dispositions of common stock.
- A total of 15,306 shares were disposed of across four transactions on July 19 and July 20, 2025.
- These dispositions were exempt transactions (code 'F') made solely to satisfy tax withholding obligations.
- The shares were related to the pre-determined vesting of restricted stock units granted in 2021, 2022, 2023, and 2024.
- The transaction prices were $8.69 per share for three dispositions and $8.99 per share for one disposition.
- Following these transactions, Mr. Clemmer beneficially owns 872,529 shares of AngioDynamics common stock.
Sentiment
Score: 5
Explanation: This is a routine, non-discretionary transaction for tax purposes related to RSU vesting, indicating no specific positive or negative sentiment about the company's prospects.
Future Outlook
No forward-looking statements or guidance are provided in this filing, as it pertains solely to an insider transaction for tax purposes.
Industry Context
This filing details a routine insider transaction common in executive compensation, where shares are disposed of to cover tax liabilities upon the vesting of restricted stock units. It does not reflect broader industry trends or competitive positioning.
Comparison to Industry Standards
- The disposition of shares to satisfy tax withholding obligations upon the vesting of restricted stock units is a standard and common practice for executives across all industries, including the medical technology sector.
- This type of transaction is a compliance requirement and does not indicate a discretionary sale based on market outlook, unlike open market sales by insiders.
Related Party Transactions
- The disposition of shares to AngioDynamics, Inc. to satisfy tax withholding obligations related to the vesting of restricted stock units is a routine related-party transaction for executive compensation.
Stakeholder Impact
- Shareholders: Minimal direct impact, as these are non-discretionary sales for tax purposes and do not reflect a change in management's confidence in the company. The number of shares disposed is small relative to total shares outstanding.
- Employees: No direct impact on employees beyond the reporting person.
Key Dates
| Date | Description |
|---|---|
| 07/21/2021 | Grant date for restricted stock units related to the disposition of 3,673 shares. |
| 07/20/2022 | Grant date for restricted stock units related to the disposition of 2,982 shares. |
| 07/19/2023 | Grant date for restricted stock units related to the disposition of 8,307 shares. |
| 07/19/2024 | Grant date for restricted stock units related to the disposition of 344 shares. |
| 07/19/2025 | Transaction date for the disposition of 344 and 8,307 shares of common stock. |
| 07/20/2025 | Transaction date for the disposition of 2,982 and 3,673 shares of common stock. |
| 07/22/2025 | Signature date of the Form 4 filing. |
Keywords
AngioDynamics, ANGO, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.